
First TROP2-directed therapy approved in the US for lung cancer
Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). It is approved in patients who have received prior EGFR-directed therapy and platinum-based chemotherapy. The indication was… Read More








